Study Finds Small Increase in Cardiovascular Risk with CGRP Inhibitors

Researchers uncover potential link between new migraine drugs and slightly elevated heart attack, stroke risk

Feb. 3, 2026 at 7:55am

Got story updates? Submit your updates here. ›

A recent study has found a small but statistically significant increase in the risk of cardiovascular events, including heart attack and stroke, among individuals newly starting treatment with calcitonin gene-related peptide (CGRP) inhibitors for migraine. While the absolute risk increase is modest, the findings have prompted calls for heightened awareness and more careful patient screening before prescribing these relatively new migraine medications.

Why it matters

CGRP inhibitors have revolutionized migraine treatment, offering new hope to millions suffering from the debilitating condition. However, this study raises concerns about a potential tradeoff between the drugs' effectiveness and a small uptick in cardiovascular risk. Understanding this potential link is crucial, as it may lead to changes in how these medications are prescribed and monitored going forward.

The details

The study, highlighted by Medscape Medical News, analyzed a large database of health records and found a slightly elevated risk of a composite outcome – including heart attack, stroke, and other cardiovascular issues – in individuals newly starting CGRP inhibitor therapy. Researchers theorize this could be due to the link between migraine itself and increased cardiovascular disease risk, or potentially a pharmacological effect of the drugs, though the exact mechanism remains unclear. Further research is needed to fully understand the relationship.

  • The study's findings were published on February 3, 2026.

The players

CGRP Inhibitors

A class of relatively new drugs, available as both injectable medications and oral forms, that target a molecule heavily involved in migraine attacks.

Medscape Medical News

The medical news publication that reported on the study highlighting the potential cardiovascular risks of CGRP inhibitors.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

What’s next

The study's findings are likely to accelerate a shift towards more personalized migraine treatment, with doctors becoming more diligent in assessing cardiovascular risk factors before prescribing CGRP inhibitors. Researchers are also actively searching for biomarkers that can predict which patients are most likely to benefit from these drugs and which might be at higher risk of adverse events.

The takeaway

This case highlights the need for heightened awareness and careful patient selection when it comes to prescribing CGRP inhibitors for migraine. While these drugs have revolutionized migraine treatment, the potential for a small increase in cardiovascular risk underscores the importance of personalized medicine and the ongoing monitoring of real-world data to ensure the safety and efficacy of these medications.